Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28029436 | 0.81 | ALDH1A1 (0.44) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| Ammonia Solution, Strong SCHEMBL27768089 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| SCHEMBL31481295 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| SCHEMBL28128795 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| SCHEMBL12588533 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| Formamide SCHEMBL29243328 | 0.73 | NOS3 (0.39) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| SCHEMBL29243315 | 0.73 | NOS3 (0.39) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| SCHEMBL8558796 | 0.71 | KMT2A (0.47) | ALDH1A1MAPTTDP1KDM4EHSD17B10 | |
| SCHEMBL9393018 | 0.69 | ALDH1A1 (0.47) | ALDH1A1MAPTTSHRTDP1GAA | |
| SCHEMBL2488382 | 0.69 | ALDH1A1 (0.41) | ALDH1A1MAPTTDP1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022207-B2 | Compound having affinity to amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20110201808-A1 | NOVEL COMPOUND HAVING AFFINITY TO AMYLOID | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20100249407-A1 | Novel Compound Having Affinity to Amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201808-A1 | NOVEL COMPOUND HAVING AFFINITY TO AMYLOID | APBA1, APP, BACE1 | ALDH1A1 942/4885MAPT 17/4885TSHR 1510/4885 |
| US-20100249407-A1 | Novel Compound Having Affinity to Amyloid | APBA1, APP, BACE1 | ALDH1A1 942/4885MAPT 17/4885TSHR 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.